作者
Yubin Gao,Zhao-Li Chen,Jia-Gen Li,Xue Hu,Xue-Jiao Shi,Zeng-Miao Sun,Fan Zhang,Zi-Ran Zhao,Zi-Tong Li,Zi-Yuan Liu,Yu Zhao,Jian Sun,Cheng Zhou,Ran Yao,Su-Ya Wang,Pan Wang,Nan Sun,Bai-Hua Zhang,Jing Dong,Yue Yu,Mei Luo,Xiao-Li Feng,Su-Sheng Shi,Fang Zhou,Feng Tan,Bin Qiu,Ning Li,Kwang‐Tsao Shao,Li Jian Zhang,Lan Jun Zhang,Qi Xue,Shu-Geng Gao,Jie He
摘要
Esophageal squamous cell carcinoma (ESCC) is one of the deadliest cancers. We performed exome sequencing on 113 tumor-normal pairs, yielding a mean of 82 non-silent mutations per tumor, and 8 cell lines. The mutational profile of ESCC closely resembles those of squamous cell carcinomas of other tissues but differs from that of esophageal adenocarcinoma. Genes involved in cell cycle and apoptosis regulation were mutated in 99% of cases by somatic alterations of TP53 (93%), CCND1 (33%), CDKN2A (20%), NFE2L2 (10%) and RB1 (9%). Histone modifier genes were frequently mutated, including KMT2D (also called MLL2; 19%), KMT2C (MLL3; 6%), KDM6A (7%), EP300 (10%) and CREBBP (6%). EP300 mutations were associated with poor survival. The Hippo and Notch pathways were dysregulated by mutations in FAT1, FAT2, FAT3 or FAT4 (27%) or AJUBA (JUB; 7%) and NOTCH1, NOTCH2 or NOTCH3 (22%) or FBXW7 (5%), respectively. These results define the mutational landscape of ESCC and highlight mutations in epigenetic modulators with prognostic and potentially therapeutic implications.